Unveiling the Temporal Dynamics of LbuCas13a Collateral RNA Cleavage in Human Cells

Van der Oost, J., Westra, E. R., Jackson, R. N. & Wiedenheft, B. Unravelling the structural and mechanistic basis of CRISPR – Cas systems. Nat. Rev. Microbiol. 12, 479–492 (2014). Mohanraju, P. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems. Science 353, aad5147 (2016). Marraffini, L. A. CRISPR-Cas immunity in prokaryotes. Nature 526, 55–61 (2015). Makarova, K. S. et al. Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nat. Rev. Microbiol. 18, 67–83 (2020). Liu, G., Lin, Q., Jin, S. & Gao, C. The CRISPR-Cas toolbox and gene editing technologies. Mol. Cell 82, 333–347 (2022). Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S. S. & Chakraborty, C. CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases. Mol. Ther. 29, 571–586 (2021). Koonin, E. V., Makarova, K. S. & Zhang, F. Diversity, classification and evolution of CRISPR-Cas systems. Curr. Opin. Microbiol. 37, 67–78 (2017). Makarova, K. S. et al. An updated evolutionary classification of CRISPR–Cas systems. Nat. Rev. Microbiol. 13, 722–736 (2015). Abudayyeh, O. O. et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353, aaf5573 (2016). Smargon, A. A. et al. Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28. Mol. Cell 65, 618–630 (2017). Konermann, S., Lotfy, P., Brideau, N. J., Oki, J. & Maxim, N. Transcriptome engineering with RNA-targeting Type VI-D CRISPR effectors. Cell https://doi.org/10.1016/j.cell.2018.02.033 (2018). Yan, W. X. et al. Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein. Mol. Cell https://doi.org/10.1016/j.molcel.2018.02.028 (2018). Xu, C. et al. Programmable RNA editing with compact CRISPR–Cas13 systems from uncultivated microbes. Nat. Methods 18, 499–506 (2021). Cox, D. B. T. et al. RNA editing with CRISPR-Cas13. Science 358, 1019–1027 (2017). East-Seletsky, A. et al. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. Nature 538, 270–273 (2016). Liu, L. et al. Two distant catalytic sites are responsible for C2c2 RNase activities. Cell 168, 121–134.e12 (2017). Zhang, C. et al. Structural basis for the RNA-guided ribonuclease activity of CRISPR-Cas13d article structural basis for the RNA-guided ribonuclease activity of CRISPR-Cas13d. Cell 175, 212–223.e17 (2018). Slaymaker, I. M. et al. High-resolution structure of Cas13b and biochemical characterization of RNA targeting and cleavage. Cell Rep. 26, 3741–3751.e5 (2019). Knott, G. J. et al. Guide-bound structures of an RNA-targeting A-cleaving CRISPR–Cas13a enzyme. Nat. Struct. Mol. Biol. https://doi.org/10.1038/nsmb.3466 (2017). Liu, L. et al. The molecular architecture for RNA-guided RNA cleavage by Cas13a. Cell 170, 714–726.e10 (2017). East-Seletsky, A. et al. RNA targeting by functionally orthogonal type VI-A CRISPR-Cas enzymes. Mol. Cell 66, 373–383 (2017). Meeske, A. J., Nakandakari-Higa, S. & Marraffini, L. A. Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage. Nature https://doi.org/10.1038/s41586-019-1257-5 (2019). Gootenberg, J. S. et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 356, 438–442 (2017). Gootenberg, J. S. et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 360, 439–444 (2018). Myhrvold, C. et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science 448, 444–448 (2018). Fozouni, P. et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell 184, 323–333 (2021). Patchsung, M. et al. Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA. Nat. Biomed. Eng. 4, 1140–1149 (2020). Arizti-Sanz, J. et al. Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2. Nat. Commun. 11, 5921 (2020). Mohanraju, P. et al. Alternative functions of CRISPR–Cas systems in the evolutionary arms race. Nat. Rev. Microbiol. 20, 351–364 (2022). Abudayyeh, O. O. et al. RNA targeting with CRISPR–Cas13. Nature https://doi.org/10.1038/nature24049 (2017). He, B. et al. Modulation of metabolic functions through Cas13d-mediated gene knockdown in liver. Protein Cell 11, 518–524 (2020). Zhang, Y. et al. Optimized RNA-targeting CRISPR/Cas13d technology outperforms shRNA in identifying functional circRNAs. Genome Biol. 22, 1–22 (2021). Li, S. et al. Screening for functional circular RNAs using the CRISPR–Cas13 system. Nat. Methods 18, 51–59 (2021). Huynh, N., Depner, N., Larson, R. & King-Jones, K. A versatile toolkit for CRISPR-Cas13-based RNA manipulation in Drosophila. Genome Biol. 21, 1–29 (2020). Kushawah, G. et al. CRISPR-Cas13d induces efficient mRNA knockdown in animal embryos. Dev. Cell 54, 805–817.e7 (2020). Zhou, H. et al. Glia-to-neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice. Cell 181, 590–603 (2020). Powell, J. E. et al. Targeted gene silencing in the nervous system with CRISPR-Cas13. Sci. Adv. 8, eabk2485 (2022). Wang, Q. et al. Efficient RNA virus targeting via CRISPR/CasRx in fish. J. Virol. 95, e0046121 (2021). Jing, X. et al. Implementation of the CRISPR-Cas13a system in fission yeast and its repurposing for precise RNA editing. Nucleic Acids Res. 46, e90 (2018). Mahas, A., Aman, R. & Mahfouz, M. CRISPR-Cas13d mediates robust RNA virus interference in plants. Genome Biol. 1, 16 (2019). Aman, R. et al. RNA virus interference via CRISPR/Cas13a system in plants. Genome Biol. 19, 1 (2018). Freije, C. A. et al. Programmable Inhibition and Detection of RNA Viruses Using Cas13. Mol. Cell https://doi.org/10.1016/J.MOLCEL.2019.09.013 (2019). Tng, P. Y. L. et al. Cas13b-dependent and Cas13b-independent RNA knockdown of viral sequences in mosquito cells following guide RNA expression. Commun. Biol. 3, 413 (2020). Blanchard, E. L. et al. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents. Nat. Biotechnol. 39, 717–726 (2021). Wang, Q. et al. The CRISPR-Cas13a gene-editing system induces collateral cleavage of RNA in glioma cells. Adv. Sci. 6, 1901299 (2019). Zhang, Z. et al. Dual-locking nanoparticles disrupt the PD-1 / PD-L1 pathway for efficient cancer immunotherapy. Adv. Mater. 1905751, 1–10 (2019). Özcan, A. et al. Programmable RNA targeting with the single-protein CRISPR effector Cas7-11. Nature 597, 720–725 (2021). Buchman, A. B. et al. Programmable RNA targeting using CasRx in flies. CRISPR J. 3, 164–176 (2020). Ai, Y., Liang, D. & Wilusz, J. E. CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells. Nucleic Acids Res. 50, 1–16 (2022). Li, Y. et al. The collateral activity of RfxCas13d can induce lethality in a RfxCas13d knock-in mouse model. Genome Biol. 24, 1–25 (2023). Shi, P. et al. Collateral activity of the CRISPR/RfxCas13d system in human cells. Commun. Biol. 6, 334 (2023). Tong, H. et al. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01419-7 (2022). Zhao, Z., Shang, P., Sage, F. & Geijsen, N. Ligation-assisted homologous recombination enables precise genome editing by deploying both MMEJ and HDR. Nucleic Acids Res. 50, e62–e62 (2022). D’Astolfo, D. S. et al. Efficient intracellular delivery of native proteins. Cell 161, 674–690 (2015). Nolan, T., Hands, R. E. & Bustin, S. A. Quantification of mRNA using real-time RT-PCR. Nat. Protoc. 1, 1559–1582 (2006). Swift, G. H., Peyton, M. J. & MacDonald, R. J. Assessment of RNA quality by semi-quantitative RT-PCR of multiple regions of a long ubiquitous mRNA. Biotechniques 28, 524–531 (2000). Auer, H. & Lyianarachchi, S. Chipping away at the chip bias: RNA degradation in microarray analysis. Nat. Genet. 35, 292–293 (2003). Bot, J. F., van der Oost, J. & Geijsen, N. The double life of CRISPR–Cas13. Curr. Opin. Biotechnol. 78, 102789 (2022). Yaguchi, K. et al. Uncoordinated centrosome cycle underlies the instability of non-diploid somatic cells in mammals. J. Cell Biol. 217, 2463–2483 (2018). Wallberg, F., Tenev, T. & Meier, P. Time-lapse imaging of cell death. Cold Spring Harb. Protoc. 2016, 251–258 (2016). Hinson, A. R. P. et al. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front. Oncol. 3, 183 (2013). Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013). Burke, J. M., Moon, S. L., Matheny, T. & Parker, R. RNase L reprograms translation by widespread mRNA turnover escaped by antiviral mRNAs. Mol. Cell 75, 1203–1217.e5 (2019). Wessels, H. H. et al. Prediction of on-target and off-target activity of CRISPR–Cas13d guide RNAs using deep learning. Nat. Biotechnol. 42, 628–637 (2024). Tieu, V. et al. A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. Cell 187, 1278–1295 (2024). Wessels, H. H. et al. Massively parallel Cas13 screens reveal principles for guide RNA design. Nat. Biotechnol. 38, 722–727 (2020). Li, Z. et al. Intrinsic targeting of host RNA by Cas13 constrains its utility. Nat. Biomed. Eng. 8, 177–192 (2023). Liu, W. et al. RNA target-independent non-canonical activation (RINCA) of Cas13 trans-nuclease activity. Sci. Bull. https://doi.org/10.1016/j.scib.2025.07.015 (2025). Martinez-Monleon, A. et al. Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup. Sci. Rep. 12, 12420 (2022). Simon, R. et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 21, 2476–2483 (2002). Amoroso, L. et al. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients. Genes Chromosomes Cancer 59, 277–285 (2020). An, H.-X. et al. Gene Amplification and Overexpression of CDK4 in Sporadic Breast Carcinomas is Associated with High Tumor Cell Proliferation. Am. J. Pathol. 154, 113–118 (1999). Wikman, H. et al. CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chromosomes Cancer 42, 193–199 (2005). Ricciotti, R. W. et al. High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: a cytogenomic microarray analysis of 47 cases. Cancer Genet. 218–219, 69–80 (2017). Mejia-Guerrero, S. et al. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer 49, 518–525 (2010). Italiano, A. et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int. J. Cancer 122, 2233–2241 (2008). Johnson, T. I. et al. Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach. EBioMedicine 68, 103396 (2021). Signorell, A. et al. DescTools: Tools for Descriptive Statistics. R package version 0.99.59, https://github.com/AndriSignorell/DescTools/ (2025). Li, H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34, 3094–3100 (2018). Dowle, M. et al. data.table: Extension of 'data.frame'. R package version 1.18.99, https://r-datatable.com (2025). Morgan, M. et al. ShortRead: a Bioconductor package for input, quality assessment and exploration of high-throughput sequence data. Bioinformatics 25, 2607–2608 (2009). Wickham, H. et al. Welcome to the Tidyverse. J. Open Source Softw. 4, 1686 (2019). Wickham, H. A Layered grammar of graphics. J. Comput. Graph. Stat. 19, 3–28 (2010). Andrews, S. FastQC: a quality control tool for high throughput sequence data [Online]. http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (2010). Wang, L., Wang, S. & Li, W. RSeQC: quality control of RNA-seq experiments. Bioinformatics 28, 2184–2185 (2012). Liao, Y., Smyth, G. K. & Shi, W. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014). Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014). Ge, S. X., Jung, D., Jung, D. & Yao, R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics 36, 2628–2629 (2020). Szklarczyk, D. et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638–D646 (2023). McQuin, C. et al. CellProfiler 3.0: next-generation image processing for biology. PLoS Biol. 16, 1–17 (2018). Kassambara, A. ggpubr: ‘ggplot2’ Based Publication Ready Plots. R package version 0.6.1, https://rpkgs.datanovia.com/ggpubr/ (2025). Wickham, H. Ggplot2 Elegant Graphics for Data Analysis https://doi.org/10.1007/978-0-387-98141-3 (Springer, 2009). Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406–3415 (2003). RNAcentral Consortium RNAcentral 2021: secondary structure integration, improved sequence search and new member databases. Nucleic Acids Res. 49, D212–D220 (2021).